HNSA — Hansa Biopharma AB Share News
0.000.00%
Last trade - 00:00- SEK4.77bn
- SEK4.38bn
- SEK222.27m
Brief: Hansa Biopharma Q2 Loss Widens To SEK 170.1 Million
Brief: Hansa Biopharma Announces $70 Mln Non-Dilutive Product Finance Transaction With NovaQuest
Europe Research Roundup: Aumann AG, Colruyt, Inchcape
Brief: Hansa Biopharma: NICE Recommends Use Of Idefirix (Imlifidase) As Desensitization Treatment
Brief: Hansa Biopharma Proposes Peter Nicklin As New Chair
Brief: Hansa Biopharma Announces Temporary Marketing Authorization In Switzerland
Brief: Hansa Biopharma Q1 Loss For Period Widens To SEK 138.4 Mln
Brief: Hansa Biopharma AB Says Treatment Idefirix Granted ASMR 3 Rating By French Transparency Commission
Brief: Hansa Biopharma And German Payer Head Association Agree On Reimbursement Price For Idefirix
Brief: Hansa Biopharma AB Announces Publication Of Important Data From An Investigator-Initiated Study In Anti-GBM In Nephrology Journal JASN
Brief: Hansa Biopharma Announces Positive Early Access Decision By French Haute Autorité De Santé To Use Idefirix as desensitization treatment for highly sensitized kidney transplant patients
Brief: Hansa Biopharma Provides Business Update Including Certain Key Financials
Brief: Hansa Biopharma Says Entered Into Agreement With AskBio To Evaluate Feasibility Of Imlifidase As Pre-Treatment Ahead Of Gene Therapy In Pompe Disease
Brief: Hansa Biopharma, Medison Pharma Sign Commercialization Partnership For Central Eastern Europe, Israel
Brief: Hansa Biopharma Confidentially Submits Draft Registration Statement to U.S. SEC
Brief: Hansa Biopharma Q3 Operating Loss Widens To SEK 148.2 Million
Europe Research Roundup: Baltic Classifieds Group, Hiscox, Zooplus
Brief: Hansa Biopharma Announces Reimbursement In The Netherlands Of Idefirix
Brief: Hansa Biopharma Q2 Operating Loss At SEK 132.4 Million